[go: up one dir, main page]

MX2015018051A - Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2. - Google Patents

Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2.

Info

Publication number
MX2015018051A
MX2015018051A MX2015018051A MX2015018051A MX2015018051A MX 2015018051 A MX2015018051 A MX 2015018051A MX 2015018051 A MX2015018051 A MX 2015018051A MX 2015018051 A MX2015018051 A MX 2015018051A MX 2015018051 A MX2015018051 A MX 2015018051A
Authority
MX
Mexico
Prior art keywords
mrna
gene expression
cancer therapy
mdm2
based gene
Prior art date
Application number
MX2015018051A
Other languages
English (en)
Other versions
MX363584B (es
Inventor
Gwen Nichols
Gong Chen
Markus Dangl
David Geho
Hua Zhong
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015018051A publication Critical patent/MX2015018051A/es
Publication of MX363584B publication Critical patent/MX363584B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud da a conocer un método para predecir la sensibilidad de un paciente, con cáncer, al tratamiento con un antagonista de MDM2 de fórmula I, II y III tal como se da a conocer en la presente memoria, comprendiendo dicho método la medición de los niveles de expresión de ARNm de por lo menos MDM2, preferentemente de un panel de cuatro genes que comprende MDM2, XPC, BBC3 y CDKN2A, como marcador biológico para predecir la respuesta.
MX2015018051A 2013-07-03 2014-07-02 Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2. MX363584B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842567P 2013-07-03 2013-07-03
US201361912781P 2013-12-06 2013-12-06
PCT/EP2014/064039 WO2015000945A1 (en) 2013-07-03 2014-07-02 Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Publications (2)

Publication Number Publication Date
MX2015018051A true MX2015018051A (es) 2016-03-16
MX363584B MX363584B (es) 2019-03-27

Family

ID=51162759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015018051A MX363584B (es) 2013-07-03 2014-07-02 Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2.

Country Status (13)

Country Link
EP (1) EP3017061B1 (es)
JP (2) JP6461126B2 (es)
KR (1) KR101879926B1 (es)
CN (1) CN105378112B (es)
AU (1) AU2014286237B2 (es)
BR (1) BR112015031542A2 (es)
CA (1) CA2912547A1 (es)
HK (1) HK1215453A1 (es)
IL (1) IL242692B (es)
MX (1) MX363584B (es)
RU (1) RU2016101514A (es)
SG (1) SG11201510816SA (es)
WO (1) WO2015000945A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
EP3094746A1 (en) * 2014-01-14 2016-11-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
JP2017532959A (ja) * 2014-10-09 2017-11-09 第一三共株式会社 Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
ES2968789T3 (es) 2015-02-20 2024-05-14 Daiichi Sankyo Co Ltd Procedimiento combinado para el tratamiento del cáncer
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
WO2018027477A1 (zh) 2016-08-08 2018-02-15 肖飞 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
WO2020018611A1 (en) * 2018-07-18 2020-01-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators
KR20180093849A (ko) 2018-08-09 2018-08-22 가톨릭대학교 산학협력단 줄기세포 사멸 예측 마커 및 이의 용도
WO2020124043A1 (en) * 2018-12-13 2020-06-18 Gordon Erlinda M Methods of exploiting oncogenic drivers along the human cyclin g1 pathway for cancer gene therapy
KR20190060964A (ko) 2019-05-24 2019-06-04 가톨릭대학교 산학협력단 줄기세포 사멸 예측 마커 및 이의 용도
EP3994696B1 (en) * 2019-07-03 2025-05-14 BostonGene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
US20230313313A1 (en) * 2020-08-27 2023-10-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
RU2766739C1 (ru) * 2021-04-12 2022-03-15 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ прогноза эффективности терапии меланомы

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1631689A2 (en) * 2003-05-28 2006-03-08 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
KR101109437B1 (ko) * 2005-12-01 2012-01-31 에프. 호프만-라 로슈 아게 항암제로서 사용하기 위한 ｐ53 및 ｍｄｍ2 단백질 간상호작용의 저해제로서의 2,4,5-트리페닐 이미다졸린유도체
EP2607497B1 (en) * 2008-05-12 2014-10-01 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
PE20110367A1 (es) 2008-09-18 2011-06-13 Hoffmann La Roche DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
US20120046186A1 (en) * 2010-08-20 2012-02-23 Pelham Robert J Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
KR20160013214A (ko) 2016-02-03
JP2019059737A (ja) 2019-04-18
AU2014286237B2 (en) 2020-08-20
WO2015000945A1 (en) 2015-01-08
JP6461126B2 (ja) 2019-01-30
BR112015031542A2 (pt) 2017-07-25
CA2912547A1 (en) 2015-01-08
SG11201510816SA (en) 2016-01-28
CN105378112A (zh) 2016-03-02
MX363584B (es) 2019-03-27
JP2016529880A (ja) 2016-09-29
EP3017061A1 (en) 2016-05-11
IL242692B (en) 2019-12-31
CN105378112B (zh) 2020-10-13
RU2016101514A3 (es) 2018-05-28
EP3017061B1 (en) 2019-01-02
AU2014286237A1 (en) 2016-01-28
KR101879926B1 (ko) 2018-08-16
HK1215453A1 (zh) 2016-08-26
RU2016101514A (ru) 2017-08-08

Similar Documents

Publication Publication Date Title
MX363584B (es) Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2.
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
EA201590554A1 (ru) Ингибиторы глюкозилцерамид-синтазы
NZ601348A (en) Methods for predicting response of triple-negative breast cancer to therapy
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
IL244421A0 (en) Methods and kits for predicting outcome, and methods and kits for treating breast cancer with radiation therapy
MX356866B (es) Biomarcadores p53.
HUE053611T2 (hu) Eljárás PI3K/AKT/mTOR inhibitor terápiás hatékonyságának elõrejelzésére PHLDA1 vagy PIK3C2B expressziója alapján
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
EA201890598A2 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
WO2015093948A3 (en) Means and methods for typing a breast cancer patient and assigning therapy based on the typing
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
AU2012236134A8 (en) Biomarkers for predicting sensitivity to cancer treatments
WO2014151606A3 (en) Methods of treating pancreatic cancer
NZ712023A (en) Caix stratification based cancer treatment
MX2015012842A (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
PT2473854T (pt) Sistemas e métodos para tratar, diagnosticar e prever a resposta à terapia do cancro de mama
BR112015020054A2 (pt) Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa
HRP20180130T1 (hr) Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras
PH12014502461A1 (en) Biomarkers for iap inhibitor therapy
EP3591050A3 (en) Use of rhoa in cancer diagnosis and inhibitor screening
WO2012019125A3 (en) Biomarkers for prostate cancer and methods for their detection
WO2014009055A9 (en) Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene.